肺癌患者结核菌感染状况

目的　探讨肺结核与肺癌的相关性。方法　运用经典抗酸染色 (ZN法 )、改良抗酸染色(IK法 )、免疫组织化学染色 (ABC法 )及TB PCR方法对 3 3 0例肺癌患者结核菌感染状况进行了前瞻性研究。结果　全组 3 3 0例纤维支气管镜刷检结核菌阳性率为 2 7.88% ;93例肺癌组织标本IK法结核菌阳性率 3 8.71% ,ABC法阳性率 5 1.6 1% ;14例手术切除标本结核菌培养阳性率 5 7.14 % ;2 0例肺癌组织切片TB PCR阳性率 6 0 %。结论　肺癌患者结核菌特别是它的L型有较高的感染率。提示肺结核与肺癌之间可能有一定的相关性。     

晚期非小细胞肺癌维持治疗的进展

肺癌的发病率和死亡率呈逐年增长趋势,其中绝大多数是非小细胞肺癌（NSCLC）,且一半以上就诊时已是ⅢB或Ⅳ期,化疗是这类患者主要治疗手段,但五年生存率仅5％～11％。如何延迟这类患者的复发时间和延长生存时间？维持治疗成为了近年研究热点之一,本文对NSCLC维持治疗的研究进展进行综述。     

辛伐他汀对慢性阻塞性肺疾病患者全身性炎症反应的影响

Objective To investigate the influence of simvastatin on inflammatory indices in nasal lavage,sputum and blood and clinical index in patients with chronic obstructive pulmonary diseases (COPD). Methods Thirty-seven stable COPD patients were randomly divided into simvastatin-treatment group (n=17),orally given simvastatin tablets for 4 weeks in addition to basic therapy,40 mg,qd) and control group (n=20),given usual med-ication). Total cell counts,percentage of leukocytes (N%) and levels of interleukin IL-8,IL-6 in nasal lavage and sputum at pre-post-treatment were compared;Serum C-reactive protein (CRP),total cholesterol (TC),low-density lipoprotein-cholesterol (LDL-C) as well as IL-8,IL-6 concentrations were measured,the variation of lung function,Sino-Nasal Outcome Test 20(SNOT-20) and St George's Respiratory Questionnaire(SGRQ) score were analyzed. Results After the treatment,the nasal lavage and sputum total cell counts,N%,IL-8 and IL-6 levels[nasal lavage: (0.7±0.3)×107/L,(41.1±10.9)%,(105.8±74.5) ng/L,(3.8±1.6) ng/L;sputum: (0.8±0.3)×109/L,(56.6±9.6) %,(2565.5±831.9) ng/L,(109.8±42.3) ng/L] dropped slightly in the simvastatin group com-pared with that at pretreatment [nasal lavage: (0.8±0.3)×107/L,(43.2±10.8) %,(107.6±86.3) ng/L,(4.1±1.9)ng/L;sputum: (0.8±0.3)×109/L,(58.1±9.3)% ,(2659.4±885.2) ng/L,(111.8±46.6) ng/L] (P>0.05) ;There were significant decreases in serum CRP [(4.3±3.7) mg/L vs (2.6±1.8) mg/L],IL-6 [(4.8±2.0)ng/L vs(4.7±1.9)ng/L] ,TC[(4.2±1.0) mmol/L vs(3.7±0.8)mmol/L] ,LDL-C[(2.4±0.5) mmol/L vs (2.2±0.5)mmol/L] (P>0.05) ;IL-8 concentrations in serum were lower gently[(6.2±1.8) ng/L vs (6.4±1.9) ng/L] (P>0.05). Significant change of simvastatin treatment on SGRQ was only reflected in the symp-tom score [pre-post-treatment:39.6±10. 8 vs 32.3±11.6,P<0.05,respectively],while other observation items (SNOT-20,FEV1%,FEV1/FVC) changed not notably (P>0.05). No marked changes in inflammatory markers and quality of life scores,lung function were observed in control group (P>0.05). Conclusion Simvastatin may be as-sociated with the potential to alleviate systemic inflammation and relieve symptoms in COPD patients.     

免疫抑制剂SIPI-96-1014的分离和鉴别

在应用酵母突变体模型筛选免疫抑制过程中，筛选出一阳性菌株ＳＩＰＩ－９６－１０１４。经过发酵提取，分离和纯化，从其菌丝体中分离出一个活性化合物ＳＩＰＩ－９６－１０１４。通过对其理化性质等光谱数据的分析，确定其结构与化合物邻羟基乙酰苯胺一致。生物学活性研究表明，其对酵母野生株和突变株具有一定的抑制活性，详细的免疫抑制活性有待于进一步研究。     

非小细胞肺癌的非手术治疗新进展

肺癌是目前世界上最常见的恶性肿瘤之一,其生存及预后极差,已成为我国恶性肿瘤死亡原因的第一位。现代医学角度分析,肺癌可分为小细胞肺癌（SCLC）和非小细胞肺癌（NSCLC）。NSCLC是指SCLC以外的所有类型的肺癌,约占所有肺癌的75％-80％。非小细胞型肺癌与小细胞癌相比其进展相对较慢,扩散转移相对较晚,恶性程度相对偏低,但约75%的患者发现时已处于中晚期,5年生存率普遍偏低.     

右上肺奇叶合并右下肺肺癌1例

奇叶是肺部少见的一种解剖变异类型,国外已有肺奇叶肺癌[1]及肺奇叶相邻肺癌的报道[2] ,但发现国内肺奇叶与肺癌同时存在的病例报道较少.本文对1例70岁男性右上肺奇叶合并右下肺肺癌的病因、临床表现、诊断、鉴别诊断及治疗进行报道.     

肺结核患者结核分支杆菌L型的检测及临床意义

对象与方法收集蚌埠医学院附属医院呼吸内科门诊及住院初治肺结核有痰患者１０２例,男６８例,女３４例,平均年龄４５（１６～８０）岁,所有病例均行ＰＰＤ试验。对以上病例痰液标本行下列检测：（１）经典抗酸染色（ＺＮ法）。（２）改良抗酸染色（ＩＫ法）,其操作及...     

辛伐他汀对慢性阻塞性肺疾病患者全身性炎症反应的影响

Objective To investigate the influence of simvastatin on inflammatory indices in nasal lavage,sputum and blood and clinical index in patients with chronic obstructive pulmonary diseases (COPD). Methods Thirty-seven stable COPD patients were randomly divided into simvastatin-treatment group (n=17),orally given simvastatin tablets for 4 weeks in addition to basic therapy,40 mg,qd) and control group (n=20),given usual med-ication). Total cell counts,percentage of leukocytes (N%) and levels of interleukin IL-8,IL-6 in nasal lavage and sputum at pre-post-treatment were compared;Serum C-reactive protein (CRP),total cholesterol (TC),low-density lipoprotein-cholesterol (LDL-C) as well as IL-8,IL-6 concentrations were measured,the variation of lung function,Sino-Nasal Outcome Test 20(SNOT-20) and St George's Respiratory Questionnaire(SGRQ) score were analyzed. Results After the treatment,the nasal lavage and sputum total cell counts,N%,IL-8 and IL-6 levels[nasal lavage: (0.7±0.3)×107/L,(41.1±10.9)%,(105.8±74.5) ng/L,(3.8±1.6) ng/L;sputum: (0.8±0.3)×109/L,(56.6±9.6) %,(2565.5±831.9) ng/L,(109.8±42.3) ng/L] dropped slightly in the simvastatin group com-pared with that at pretreatment [nasal lavage: (0.8±0.3)×107/L,(43.2±10.8) %,(107.6±86.3) ng/L,(4.1±1.9)ng/L;sputum: (0.8±0.3)×109/L,(58.1±9.3)% ,(2659.4±885.2) ng/L,(111.8±46.6) ng/L] (P>0.05) ;There were significant decreases in serum CRP [(4.3±3.7) mg/L vs (2.6±1.8) mg/L],IL-6 [(4.8±2.0)ng/L vs(4.7±1.9)ng/L] ,TC[(4.2±1.0) mmol/L vs(3.7±0.8)mmol/L] ,LDL-C[(2.4±0.5) mmol/L vs (2.2±0.5)mmol/L] (P>0.05) ;IL-8 concentrations in serum were lower gently[(6.2±1.8) ng/L vs (6.4±1.9) ng/L] (P>0.05). Significant change of simvastatin treatment on SGRQ was only reflected in the symp-tom score [pre-post-treatment:39.6±10. 8 vs 32.3±11.6,P<0.05,respectively],while other observation items (SNOT-20,FEV1%,FEV1/FVC) changed not notably (P>0.05). No marked changes in inflammatory markers and quality of life scores,lung function were observed in control group (P>0.05). Conclusion Simvastatin may be as-sociated with the potential to alleviate systemic inflammation and relieve symptoms in COPD patients.     

阿奇霉素治疗呼吸道感染

目的 :观察阿奇霉素对呼吸道感染的疗效。方法 :75例呼吸道感染病人随机分为阿奇霉素组 4 0例 [男性 2 6例 ,女性 14例 ,年龄 34a±s10a (18～6 0a) ],用阿奇霉素 0 .2 5g +5%葡萄糖注射液 50 0mL ,iv ,gtt ,qd ,首日剂量加倍 ,疗程 5d ;头孢唑林组 35例 [男性 2 3例 ,女性 12例 ,年龄 33a± 11a(18～ 59a) ],用头孢唑林 2 g +5%葡萄糖注射液2 50mL ,iv ,gtt ,bid ,疗程 5d。结果 :阿奇霉素组和头孢唑林组的总有效率分别为 95%和 94 % ,细菌清除率分别为 97%和 97% ,不良反应发生率分别为 8%和 9% ,P >0 .0 5。结论 :阿奇霉素是治疗呼吸道感染有效、不良反应少的药物